{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:23:50Z","timestamp":1789885430210,"version":"4.0.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s40265-016-0565-4","type":"journal-article","created":{"date-parts":[[2016,4,6]],"date-time":"2016-04-06T10:57:13Z","timestamp":1459940233000},"page":"639-646","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to Date"],"prefix":"10.1007","volume":"76","author":[{"given":"Till","family":"Seiler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grit","family":"Hutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,6]]},"reference":[{"issue":"5573","key":"565_CR1","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1126\/science.296.5573.1655","volume":"296","author":"LC Cantley","year":"2002","unstructured":"Cantley LC. The phosphoinositide 3-kinase pathway. Science (New York, NY). 2002;296(5573):1655\u20137.","journal-title":"Science (New York, NY)."},{"issue":"8","key":"565_CR2","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrd2926","volume":"8","author":"P Liu","year":"2009","unstructured":"Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009;8(8):627\u201344.","journal-title":"Nat Rev Drug Discov."},{"issue":"7","key":"565_CR3","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0968-0004(97)01061-X","volume":"22","author":"B Vanhaesebroeck","year":"1997","unstructured":"Vanhaesebroeck B, Leevers SJ, Panayotou G, Waterfield MD. Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem Sci. 1997;22(7):267\u201372.","journal-title":"Trends Biochem Sci"},{"issue":"3","key":"565_CR4","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrm3290","volume":"13","author":"B Vanhaesebroeck","year":"2012","unstructured":"Vanhaesebroeck B, Stephens L, Hawkins P. PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol. 2012;13(3):195\u2013203.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"565_CR5","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1146\/annurev.cellbio.17.1.615","volume":"17","author":"R Katso","year":"2001","unstructured":"Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol. 2001;17:615\u201375.","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"8","key":"565_CR6","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/nrg1879","volume":"7","author":"JA Engelman","year":"2006","unstructured":"Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7(8):606\u201319.","journal-title":"Nat Rev Genet"},{"issue":"5","key":"565_CR7","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nrm3330","volume":"13","author":"MS Song","year":"2012","unstructured":"Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012;13(5):283\u201396.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"565_CR8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/bjh.13065","volume":"167","author":"JS Blachly","year":"2014","unstructured":"Blachly JS, Baiocchi RA. Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma. Br J Haematol. 2014;167(1):19\u201332.","journal-title":"Br J Haematol"},{"issue":"Pt 1","key":"565_CR9","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1042\/bst0310270","volume":"31","author":"K Okkenhaug","year":"2003","unstructured":"Okkenhaug K, Vanhaesebroeck B. PI3K-signalling in B- and T-cells: insights from gene-targeted mice. Biochem Soc Trans. 2003;31(Pt 1):270\u20134.","journal-title":"Biochem Soc Trans"},{"issue":"3","key":"565_CR10","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nri2036","volume":"7","author":"C Rommel","year":"2007","unstructured":"Rommel C, Camps M, Ji H. PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat Rev Immunol. 2007;7(3):191\u2013201.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"565_CR11","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jaci.2014.02.020","volume":"134","author":"S Kracker","year":"2014","unstructured":"Kracker S, Curtis J, Ibrahim MA, Sediva A, Salisbury J, Campr V, et al. Occurrence of B-cell lymphomas in patients with activated phosphoinositide 3-kinase delta syndrome. J Allergy Clin Immunol. 2014;134(1):233\u20136.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"565_CR12","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s10875-014-0012-9","volume":"34","author":"MC Crank","year":"2014","unstructured":"Crank MC, Grossman JK, Moir S, Pittaluga S, Buckner CM, Kardava L, et al. Mutations in PIK3CD can cause hyper IgM syndrome (HIGM) associated with increased cancer susceptibility. J Clin Immunol. 2014;34(3):272\u20136.","journal-title":"J Clin Immunol"},{"issue":"1","key":"565_CR13","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1042\/BJ20111741","volume":"442","author":"IM Berenjeno","year":"2012","unstructured":"Berenjeno IM, Guillermet-Guibert J, Pearce W, Gray A, Fleming S, Vanhaesebroeck B. Both p110alpha and p110beta isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor. Biochem J. 2012;442(1):151\u20139.","journal-title":"Biochem J"},{"issue":"12","key":"565_CR14","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0006-2952(97)00169-X","volume":"53","author":"M Nakamura","year":"1997","unstructured":"Nakamura M, Nakashima S, Katagiri Y, Nozawa Y. Effect of wortmannin and 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) on N-formyl-methionyl-leucyl-phenylalanine-induced phospholipase D activation in differentiated HL60 cells: possible involvement of phosphatidylinositol 3-kinase in phospholipase D activation. Biochem Pharmacol. 1997;53(12):1929\u201336.","journal-title":"Biochem Pharmacol"},{"issue":"Pt 2","key":"565_CR15","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1042\/BST0350245","volume":"35","author":"ZA Knight","year":"2007","unstructured":"Knight ZA, Shokat KM. Chemically targeting the PI3K family. Biochem Soc Trans. 2007;35(Pt 2):245\u20139.","journal-title":"Biochem Soc Trans"},{"issue":"1","key":"565_CR16","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.bbapap.2007.10.003","volume":"1784","author":"R Marone","year":"2008","unstructured":"Marone R, Cmiljanovic V, Giese B, Wymann MP. Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta. 2008;1784(1):159\u201385.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"565_CR17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1042\/BJ20110502","volume":"438","author":"S Jamieson","year":"2011","unstructured":"Jamieson S, Flanagan JU, Kolekar S, Buchanan C, Kendall JD, Lee WJ, et al. A drug targeting only p110alpha can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types. Biochem J. 2011;438(1):53\u201362.","journal-title":"Biochem J"},{"issue":"5","key":"565_CR18","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nm1232","volume":"11","author":"SP Jackson","year":"2005","unstructured":"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, et al. PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med. 2005;11(5):507\u201314.","journal-title":"Nat Med"},{"issue":"2","key":"565_CR19","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","volume":"117","author":"BJ Lannutti","year":"2011","unstructured":"Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011;117(2):591\u20134.","journal-title":"Blood"},{"issue":"3","key":"565_CR20","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1042\/BJ20070003","volume":"404","author":"C Chaussade","year":"2007","unstructured":"Chaussade C, Rewcastle GW, Kendall JD, Denny WA, Cho K, Gronning LM, et al. Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. Biochem J. 2007;404(3):449\u201358.","journal-title":"Biochem J"},{"issue":"11","key":"565_CR21","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.chembiol.2013.09.017","volume":"20","author":"DG Winkler","year":"2013","unstructured":"Winkler DG, Faia KL, DiNitto JP, Ali JA, White KF, Brophy EE, et al. PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013;20(11):1364\u201374.","journal-title":"Chem Biol"},{"issue":"21","key":"565_CR22","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1182\/blood.V124.21.3123.3123","volume":"124","author":"G Hutter","year":"2014","unstructured":"Hutter G, Zimmermann Y, Zoellner AK, Irrgang P, Weigert O, Hiddemann W, et al. Combination of PI3K and PDPK1 inhibitors is highly effective in mantle cell lymphoma. Blood. 2014;124(21):3123.","journal-title":"Blood"},{"issue":"22","key":"565_CR23","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","volume":"123","author":"JR Brown","year":"2014","unstructured":"Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed\/refractory chronic lymphocytic leukemia. Blood. 2014;123(22):3390\u20137.","journal-title":"Blood"},{"issue":"11","key":"565_CR24","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997\u20131007.","journal-title":"N Engl J Med"},{"issue":"13","key":"565_CR25","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","volume":"118","author":"J Hoellenriegel","year":"2011","unstructured":"Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, et al. The phosphoinositide 3\u2019-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011;118(13):3603\u201312.","journal-title":"Blood"},{"key":"565_CR26","doi-asserted-by":"crossref","unstructured":"Sharman JP, Coutre SE, Furman RF, Cheson BD, Pagel JM, Hillmen P, et al. Second interim analysis of a phase 3 study of idelalisib (ZYDELIG\u00ae) plus rituximab (R) for relapsed chronic lymphocytic leukemia (CLL): efficacy analysis in patient subpopulations with Del(17p) and other adverse prognostic factors. Blood. 2014:Abstract 330.","DOI":"10.1182\/blood.V124.21.330.330"},{"key":"565_CR27","doi-asserted-by":"crossref","unstructured":"O\u2019BrienS., Lamanna N, Kipps TJ, Flinn IW, Zelenetz AD, Burger JA, et al. Update on a phase 2 study of idelalisib in combination with rituximab in treatment-na\u00efve patients \u226565\u00a0years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Blood. 2014:Abstract 1994.","DOI":"10.1182\/blood.V124.21.1994.1994"},{"key":"565_CR28","doi-asserted-by":"crossref","unstructured":"Furman R, de Vos S, Barrientos JC, Schreeder MT, Flinn IW, Sharman JP, et al. Long-term follow-up of a phase 1 study of idelalisib (ZYDELIG\u00ae) in combination with anti-CD20 antibodies (rituximab [R] or ofatumumab [O]) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood. 2014;124(21) [abstract 5653].","DOI":"10.1182\/blood.V124.21.5653.5653"},{"key":"565_CR29","doi-asserted-by":"crossref","unstructured":"Barrientos JC, Coutre SE, de Vos S, Wagner-Johnston NC, Flinn IW, Sharman JP, et al. Long-term follow-up of a phase 1 trial of idelalisib (ZYDELIG\u00ae) in combination with bendamustine (B), bendamustine\/rituximab (BR), fludarabine (F), chlorambucil (Chl), or chlorambucil\/rituximab (ChlR) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood. 2014:Abstract 3343.","DOI":"10.1182\/blood.V124.21.3343.3343"},{"key":"565_CR30","doi-asserted-by":"crossref","unstructured":"Zelenetz AD, Robak T, Coiffier B, Delgado J, Marlton P, Adewoye AH, et al. Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed\/refractory chronic lymphocytic leukemia: results of a phase 3 randomized double-blind placebo-controlled study. Blood. 2015:LBA 5.","DOI":"10.1182\/blood.V126.23.LBA-5.LBA-5"},{"issue":"22","key":"565_CR31","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1182\/blood-2013-11-538546","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, Kahl BS, Leonard JP, Furman RR, Brown JR, Byrd JC, et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014;123(22):3406\u201313.","journal-title":"Blood"},{"issue":"11","key":"565_CR32","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","volume":"370","author":"AK Gopal","year":"2014","unstructured":"Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008\u201318.","journal-title":"N Engl J Med"},{"key":"565_CR33","doi-asserted-by":"crossref","unstructured":"Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak W, et al. Mature follow up from a phase 2 study of PI3K-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)-refractory indolent B-cell non-hodgkin lymphoma (iNHL). Blood. 2014:Abstract 1708.","DOI":"10.1182\/blood.V124.21.1708.1708"},{"key":"565_CR34","doi-asserted-by":"crossref","unstructured":"de Vos S, Wagner-Johnston ND, Coutre SE, Flinn I, Schreeder MT, Fowler N, et al. Durable responses following treatment with the PI3K-delta inhibitor idelalisib in combination with rituximab, bendamustine, or both, in recurrent indolent non-Hodgkin lymphoma: phase I\/II results. Blood. 2014:Abstract 3063.","DOI":"10.1182\/blood.V124.21.3063.3063"},{"issue":"22","key":"565_CR35","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","volume":"123","author":"BS Kahl","year":"2014","unstructured":"Kahl BS, Spurgeon SE, Furman RR, Flinn IW, Coutre SE, Brown JR, et al. A phase 1 study of the PI3Kdelta inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL). Blood. 2014;123(22):3398\u2013405.","journal-title":"Blood"},{"key":"565_CR36","doi-asserted-by":"crossref","unstructured":"Wagner-Johnston ND, De Vos S, Leonard J, Sharman JP, Schreeder MT, Boccia RV, et al. Preliminary results of PI3K\u03b4 inhibitor idelalisib (GS-1101) treatment in combination with everolimus, bortezomib, or bendamustine\/rituximab in patients with previously treated mantle cell lymphoma (MCL). J Clin Oncol. 2013;31(suppl):Abstract 8501.","DOI":"10.1200\/jco.2013.31.15_suppl.8501"},{"issue":"10","key":"565_CR37","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.3109\/10428194.2015.1022770","volume":"56","author":"SE Coutre","year":"2015","unstructured":"Coutre SE, Barrientos JC, Brown JR, de Vos S, Furman RR, Keating MJ, et al. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma. 2015;56(10):2779\u201386.","journal-title":"Leuk Lymphoma"},{"key":"565_CR38","doi-asserted-by":"crossref","unstructured":"O\u2019Brien S, Patel M, Kahl BS, Horwitz SM, Foss FM, Prcu P, et al. Duvelisib (IPI-145), a PI3K-\u03b4,\u03b3 inhibitor, is clinically active in patients with relapsed\/refractory chronic lymphocytic leukemia. Blood. 2014:Abstract 3334.","DOI":"10.1182\/blood.V124.21.3334.3334"},{"key":"565_CR39","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1182\/blood.V126.23.4158.4158","volume":"126","author":"MS Davids","year":"2015","unstructured":"Davids MS, Kim HT, Gilbert E, Cowen L, Francoeur K, Hellman J, et al. Preliminary Results of a phase Ib study of duvelisib in combination with FCR (dFCR) in previously untreated, younger patients with CLL. Blood. 2015;126:4158.","journal-title":"Blood"},{"key":"565_CR40","doi-asserted-by":"crossref","unstructured":"Flinn I, Oki Y, Patel M, Horwitz SM, Foss FM, Sweeney J, et al. A phase 1 evaluation of duvelisib (IPI-145), a PI3K-\u03b4,\u03b3 inhibitor, in patients with relapsed\/refractory iNHL. Blood. 2014:Abstract 802.","DOI":"10.1182\/blood.V124.21.802.802"},{"key":"565_CR41","doi-asserted-by":"crossref","unstructured":"Flinn I, Patel MR, Maris MB, Matous J, Cherry M, Berdeja JG. An open-label, phase Ib study of duvelisib (IPI-145) in combination with bendamustine, rituximab or bendamustine\/rituximab in select subjects with lymphoma or chronic lymphocytic leukemia. Blood. 2014:Abstract 4422.","DOI":"10.1182\/blood.V124.21.4422.4422"},{"key":"565_CR42","doi-asserted-by":"crossref","unstructured":"Horwitz SM, Porcu P, Flinn I, Kahl BS, Sweeney J, Stern HM, et al. Duvelisib (IPI-145), a phosphoinositide-3-kinase-\u03b4,\u03b3 inhibitor, shows activity in patients with relapsed\/refractory T-cell lymphoma. Blood. 2014:Abstract 803.","DOI":"10.1182\/blood.V124.21.803.803"},{"key":"565_CR43","doi-asserted-by":"crossref","unstructured":"Dreyling MH, Morschhauser F, Bron D, Bouabdallah K, Vitolo U, Linton K, et al. Preliminary results of a phase II study of single agent Bay 80-6946, a novel PI3K inhibitor, in patients with relapsed\/refractory, indolent or aggressive lymphoma. Blood. 2013:Abstract 87.","DOI":"10.1182\/blood.V122.21.87.87"},{"key":"565_CR44","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1182\/blood.V126.23.3935.3935","volume":"126","author":"D Cunningham","year":"2015","unstructured":"Cunningham D, Zinzani PL, Assouline SE, Bouabdallah K, Bron D, Haioun C, et al. Results of the mantle cell lymphoma subset from a phase 2a study of copanlisib, a novel PI3K inhibitor, in patients with indolent and aggressive lymphoma. Blood. 2015;126:3935.","journal-title":"Blood"},{"issue":"12","key":"565_CR45","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1182\/blood-2012-10-460832","volume":"121","author":"S Iyengar","year":"2013","unstructured":"Iyengar S, Clear A, Bodor C, Maharaj L, Lee A, Calaminici M, et al. P110alpha-mediated constitutive PI3K signaling limits the efficacy of p110delta-selective inhibition in mantle cell lymphoma, particularly with multiple relapse. Blood. 2013;121(12):2274\u201384.","journal-title":"Blood"},{"key":"565_CR46","doi-asserted-by":"crossref","unstructured":"Matas-C\u00e9spedes A, Rodriguez V, Kalko S, Gine E, Campo E, Roue G, et al. Follicular dendrytic cells deliver angiogenesis signaling to follicular lymphoma cells that is hampered by the Pan-PI3K inhibitor NVP-BKM120. Blood. 2013:Abstract 3072.","DOI":"10.1182\/blood.V122.21.3072.3072"},{"key":"565_CR47","doi-asserted-by":"crossref","unstructured":"Herko A, Mavis C, Czuczman MS, Hernandez F. AMG 319, a novel inhibitor of phosphoinositide-3 kinase delta (PI3Kd), demonstrates activity in lymphoma pre-clinical models. Blood. 2012:Abstract 3718.","DOI":"10.1182\/blood.V120.21.3718.3718"},{"key":"565_CR48","doi-asserted-by":"crossref","unstructured":"Savona M, Gutierrez M-, Lanasa M, Deng C, Kuhn J, Sade L, et al. A phase I dose escalation study of TGR-1202, a novel PI3K-\u03b4 inhibitor, for patients with relapsed or refractory hematologic malignancies. Blood. 2013:Abstract 4373.","DOI":"10.1182\/blood.V122.21.4373.4373"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0565-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-016-0565-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0565-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T07:02:16Z","timestamp":1600412536000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-016-0565-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["565"],"URL":"https:\/\/doi.org\/10.1007\/s40265-016-0565-4","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}